×
About 508 results

ALLMedicine™ Generalized Lipodystrophy Center

Research & Reviews  245 results

Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression ...
https://doi.org/10.1016/j.metabol.2020.154341
Metabolism: Clinical and Experimental; Tapia PJ, Figueroa AM et. al.

Aug 18th, 2020 - Biallelic loss of function variants in AGPAT2, encoding 1-acylglycerol-3-phosphate O-acyltransferase 2, cause congenital generalized lipodystrophy type 1, a disease characterized by near total loss of white adipose tissue and metabolic complicatio...

Novel compound heterozygous variant of BSCL2 identified by whole exome sequencing and m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185175
Molecular Medicine Reports; Xie B, Fan X et. al.

Apr 2nd, 2020 - Congenital generalized lipodystrophy (CGL) is a clinically and genetically heterogeneous condition with autosomal recessive inheritance. CGL is classified into four subtypes on the basis of causative genes. This study reported on a 2‑month‑old mal...

Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance cond...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033930
Journal of Medical Case Reports; Guerreiro V, Bernardes I et. al.

Feb 22nd, 2020 - Lipodystrophies are a group of diseases which are characterized by abnormal adipose tissue deposition and are frequently associated with metabolic changes. Congenital generalized lipodystrophy is an autosomal recessive syndrome, with a prevalence ...

GPAT3 deficiency alleviates insulin resistance and hepatic steatosis in a mouse model o...
https://doi.org/10.1093/hmg/ddz300
Human Molecular Genetics; Gao M, Liu L et. al.

Dec 24th, 2019 - Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is the most severe form of human lipodystrophy and is caused by loss-of-function mutations in the BSCL2/seipin gene. Exactly how seipin may regulate adipogenesis remains unclear. A recent s...

Mandibuloacral dysplasia type B (MADB): a cohort of eight patients from Suriname with a...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6924056
Orphanet Journal of Rare Diseases; Hitzert MM, van der Crabben SN et. al.

Dec 20th, 2019 - Mandibuloacral Dysplasia with type B lipodystrophy (MADB) is a rare premature aging disorder with an autosomal recessive inheritance pattern. MADB is characterized by brittle hair, mottled, atrophic skin, generalized lipodystrophy, insulin resista...

see more →

Guidelines  1 results

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →

Drugs  4 results see all →

Clinicaltrials.gov  255 results

Absence of AGPAT2 impairs brown adipogenesis, increases IFN stimulated gene expression ...
https://doi.org/10.1016/j.metabol.2020.154341
Metabolism: Clinical and Experimental; Tapia PJ, Figueroa AM et. al.

Aug 18th, 2020 - Biallelic loss of function variants in AGPAT2, encoding 1-acylglycerol-3-phosphate O-acyltransferase 2, cause congenital generalized lipodystrophy type 1, a disease characterized by near total loss of white adipose tissue and metabolic complicatio...

Myalept - metreleptin injection, powder, lyophilized, for solution-Aegerion Pharmaceuticals, Inc.
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c986f93b-855d-4ef0-b620-5d41a0513e48

May 25th, 2020 - MYALEPT is a leptin analog indicated as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired generalized lipodystrophy. (1) Limitations of Use The safety and effectivenes...

Novel compound heterozygous variant of BSCL2 identified by whole exome sequencing and m...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7185175
Molecular Medicine Reports; Xie B, Fan X et. al.

Apr 2nd, 2020 - Congenital generalized lipodystrophy (CGL) is a clinically and genetically heterogeneous condition with autosomal recessive inheritance. CGL is classified into four subtypes on the basis of causative genes. This study reported on a 2‑month‑old mal...

Acromegaly with congenital generalized lipodystrophy - two rare insulin resistance cond...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7033930
Journal of Medical Case Reports; Guerreiro V, Bernardes I et. al.

Feb 22nd, 2020 - Lipodystrophies are a group of diseases which are characterized by abnormal adipose tissue deposition and are frequently associated with metabolic changes. Congenital generalized lipodystrophy is an autosomal recessive syndrome, with a prevalence ...

GPAT3 deficiency alleviates insulin resistance and hepatic steatosis in a mouse model o...
https://doi.org/10.1093/hmg/ddz300
Human Molecular Genetics; Gao M, Liu L et. al.

Dec 24th, 2019 - Berardinelli-Seip congenital lipodystrophy type 2 (BSCL2) is the most severe form of human lipodystrophy and is caused by loss-of-function mutations in the BSCL2/seipin gene. Exactly how seipin may regulate adipogenesis remains unclear. A recent s...

see more →

News  3 results

FDA approves Bristol-Myers' drug for rare fat disorder
https://www.reuters.com/article/us-bristolmyers-fda/fda-approves-bristol-myers-drug-for-rare-fat-disorder-idUSBREA1O18920140226

Feb 26th, 2014 - (Reuters) - The U.S. Food and Drug Administration said it approved Bristol-Myers Squibb Co’s drug to treat rare and potentially fatal disorders involving loss of body fat. The condition, known as generalized lipodystrophy, involves fat buildup in ...

FDA advisory panel partially backs drug for rare fat disorder
https://www.reuters.com/article/us-fda-bristolmyers/fda-advisory-panel-partially-backs-drug-for-rare-fat-disorder-idUSBRE9BA1A020131211

Dec 11th, 2013 - (Reuters) - An advisory panel of medical experts convened by the U.S. Food and Drug Administration on Wednesday said that Bristol-Myers Squibb Co had provided adequate evidence of the benefits of an experimental drug to treat rare and potentially ...

MYALEPT® (metreleptin)
http://www.myaleptpro.com/

Learn more about MYALEPT (metreleptin) for injection, indicated as an adjunct to diet to treat complications of leptin deficiency in patients with generalized lipodystrophy

see more →